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Abstract
Background:  Measuring the quantity of miRNAs in tissues of different physiological and
pathological conditions is an important first step to investigate the functions of miRNAs. Matched
samples from normal state can provide essential baseline references to analyze the variation of
miRNA abundance.
Results:  We provided expression data of 345 miRNAs in 40 normal human tissues, which
identified universally expressed miRNAs, and several groups of miRNAs expressed exclusively or
preferentially in certain tissue types. Many miRNAs with co-regulated expression patterns are
located within the same genomic clusters, and candidate transcriptional factors that control the
pattern of their expression may be identified by a comparative genomic strategy. Hierarchical
clustering of normal tissues by their miRNA expression profiles basically followed the structure,
anatomical locations, and physiological functions of the organs, suggesting that functions of a
miRNA could be appreciated by linking to the biologies of the tissues in which it is uniquely
expressed. Many predicted target genes of miRNAs that had specific reduced expression in brain
and peripheral blood mononuclear cells are required for embryonic development of the nervous
and hematopoietic systems based on database search.
Conclusion: We presented a global view of tissue distribution of miRNAs in relation to their
chromosomal locations and genomic structures. We also described evidence from the cis-
regulatory elements and the predicted target genes of miRNAs to support their tissue-specific
functional roles to regulate the physiologies of the normal tissues in which they are expressed.
Background
MicroRNAs (miRNAs) belong to a family of small non-
coding RNAs (18~22 nucleotides) that interact with their
target coding mRNAs to inhibit translation by either deg-
radation of the mRNAs, or blocking translation without
degrading the targets [1]. Significant conservation of indi-
vidual miRNAs across different species suggests their func-
tional importance. It has been shown in several animal
models that miRNAs participate in determination of cell
fate, pattern formation in embryonic development, and in
control of cell proliferation, cell differentiation, and cell
death [2]. Therefore, it is reasonable to speculate that miR-
NAs are also involved in human diseases such as cancers
[3]. Several groups of miRNAs have been identified to reg-
ulate the expression of tumor-associated genes [4], while
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others seem to hold prognostic value in predicting the sur-
vival of cancer patients [5].
Chromosomal location and genomic distribution of a
miRNA gene are important determinants of its expression
from at least three perspectives. First, about 80% of
miRNA genes are located within introns of defined tran-
scription units [6], and their expression is frequently cor-
related with the expression profiles of their host genes
[7,8]. Second, many miRNA genes are distributed as clus-
ters, and a microarray expression profiling of 175 miRNAs
in 24 human tissues showed that proximally paired
miRNA genes at a distance up to 50 kb are generally co-
expressed [8]. The best example may be the four miRNA
genes (miR-196b, miR-10a, miR-196a-2, and miR-10b)
that are embedded in the Hox gene clusters (Hox A, Hox B,
Hox C, and Hox D, respectively). By histochemical staining
and in situ hybridization, expression patterns of miR-10a
and Hoxb4 mRNA are very similar, suggesting that they
share regulatory control of transcription [9]. Lastly,
miRNA genes are frequently located at fragile sites, as well
as in regions of loss of heterozygosity, regions of amplifi-
cation, or common breakpoint regions [10]. Expression of
miRNA genes within the regions afflicted by chromo-
somal aberration, a hallmark characteristic of neoplastic
cells, could also be directly affected. For example, miR-15a
and miR-16-1 are located at a frequently deleted site in
most of the B cell chronic lymphocytic leukemia patients
[11], and induce apoptosis in a leukemia cell line model
[12].
Most expression profiling of miRNAs in normal human
tissues has been explored in a rather small collection of
tissues or miRNAs, in which some of them were restricted
by time-consuming and laborious strategies such as
Northern blotting or cloning [13]. One report used a
bead-based detection platform to profile expression of
217 miRNAs in a broad spectrum of normal human tis-
sues, but low sensitivity and specificity make the results
problematic for miRNAs that are less abundant [14].
Microarrays have the advantage of high throughput and
was used for profiling expression of miRNAs [8,15,16],
but they have the same concern of sensitivity, and it might
be difficult for them to differentiate closely related miR-
NAs in sequences.
Sensitivity is always a major obstacle to examine tissue-
specific expression patterns of miRNAs with low abun-
dance. A new type of real time reverse transcription (RT)-
PCR-based miRNA assays were recently developed that
have better sensitivity and specificity compared to bead-
and microarray-based technologies [17]. We used these
assays to examine global profiles of distribution and
expression of 345 unique miRNAs in 40 normal human
tissues, so we could identify tissue-specific miRNAs that
provide foundations to pursue diagnostic and therapeutic
targets as well as molecular mechanisms underlying the
phenotypic diversity of different tissues, and present uni-
versal baselines for investigating variations in miRNA
expression under physiological or pathological condi-
tions. Our data were also combined with public datasets
to systematically analyze the association between
genomic locations of miRNAs and their expression, and
the correlation of expression between miRNAs and their
predicted target genes.
Results
Hierarchical clustering of normal human tissues is mainly 
based on their anatomical locations and physiological 
functions using the miRNA expression profiles
To assess the reproducibility of the TaqMan® MicroRNA
Assays, we characterized the expression of miRNAs in
three brain, two testes, and two peripheral blood mono-
nuclear cells (PBMC) specimens. We found a high con-
cordance between the three brain specimens (r = 0.945
and 0.952, respectively, Figure 1A), between the two testes
(r = 0.975, Figure 1B), and to a lesser extent between the
two PBMC samples (r = 0.738, Figure 1C). To demon-
strate the repeatability of the data during the course of our
studies, we examined the expression of miRNAs in the
same lung tissue at four different time points within a five-
month time frame, and the abundance of miRNAs we
measured were highly consistent at all times (r > 0.98, Fig-
ure 1D).
Scatter plots demonstrate the reproducibility and repeatabil- ity of the TaqMan® miRNA assays Figure 1
Scatter plots demonstrate the reproducibility and repeatabil-
ity of the TaqMan® miRNA assays. We examined the miRNA 
expression in three brain (A), two testes (B), and two PBMC 
(C) specimens. Assays that had CT values > 35 were removed 
from the analysis and correlation of the data were evaluated 
by Spearman test. Expression of miRNAs was also examined 
in the same lung specimen at four different time points (T1 to 
T4) within a five-month time frame to show the repeatability 
of the data (D).BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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The expression of 345 human miRNAs was quantitated in
a spectrum of 40 normal human tissues that included
specimens derived from brain, muscle, circulatory, respi-
ratory, lymphoid, gastrointestinal, urinary, reproductive,
and endocrine systems (see Additional file 1). We
employed an unsupervised hierarchical clustering based
on the variation of expression for each miRNA across the
specimens examined to explore the correlation between
different tissue types. In general, normal human tissues
derived from similar anatomical locations or with related
physiological functions were primarily clustered together
(Figure 2). For example, tissues derived from different
parts of heart (atrium versus ventricle) were clustered with
skeletal muscle. Tissues from the gastrointestinal system
Unsupervised hierarchical clustering of the normal human tissues based on the variation of miRNA expression correlates with  the anatomical locations and physiological functions of the tissues Figure 2
Unsupervised hierarchical clustering of the normal human tissues based on the variation of miRNA expression correlates with 
the anatomical locations and physiological functions of the tissues. Normalized CT for each assay was transformed into ∆CT 
against the average CT of all assays examined and clustered after mean-centering the data for each miRNA but no centering 
was done for the tissues. A detailed view of the clustering patterns of normal tissues is on the right. The blue bar on the left 
side of the heat map represented the group of miRNAs primarily expressed in placenta, and the red bar indicated the miRNAs 
with significant increased expression in epithelial tissues including the gastrointestinal organs. A pseudocolor scale bar repre-
sented the fold change relative to the mean of the data for each miRNA.BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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(stomach, small intestine, and colon), lymphoid tissues
(spleen and lymph node), female reproductive organs
(ovary, uterus, and cervix), and respiratory tissues (lung
and trachea) were also together, respectively, as shown in
Figure 2. This result recapitulated the previously pub-
lished clustering patterns of normal tissues using mRNA
expression profiles [18].
However, the clustering patterns among some tissue types
by their mRNA and our miRNA expression profiles were
quite different (see Additional file 2). Lung was clustered
together with female reproductive organs and esophagus
by mRNA expression profile, but miRNA expression pro-
file of lung was only similar to that of Fallopian tube. Thy-
roid was similar to different parts of the heart in miRNA
expression but not in mRNA expression. Liver was clus-
tered together with the gastrointestinal organs and kidney
by mRNA expression profiles but not when the miRNA
expression profiles were used. Brain, PBMC, thymus, adre-
nal gland, and testes formed a unique cluster separate
from the other tissues by their miRNA expression profiles,
but such similarities in mRNA expression profiles
between these five tissue types were only observed sepa-
rately between brain and testes, and between thymus and
PBMC [18].
Some groups of miRNAs demonstrated highly differential
patterns of tissue distribution that were not seen in the
mRNA profiles. For example, a prominent expression of a
group of miRNAs (miR-141, miR-200 family, miR-429,
miR-375, and miR-31) mainly in epithelial tissues, such
as lung, breast, and the gastrointestinal organs (r = 0.72,
Figure 2), contributed to separate all the normal tissues
examined into two parts. A neighboring group of miRNAs
(miR-192, miR-194, and miR-215) shared similar expres-
sion patterns but particularly in the gastrointestinal
organs (r = 0.912, Figure 2). A large number (~100) of
miRNAs had pronounced expression in placenta com-
pared to most of the other tissues.
Localization in the same genomic cluster is the most 
recognizable feature for miRNAs that have correlated 
abundance and expression patterns among tissues
Centered expression data for each miRNA as shown in Fig-
ure 2 describes the "pattern" of expression in tissues with-
out regarding the abundance of that miRNA, but
identification of tissue-specific markers or potential diag-
nostic/therapeutic targets requires unmodified quantita-
tive measurements from the TaqMan®  assays. Our
uncentered expression data revealed both miRNAs univer-
sally expressed in all tissues as well as those differentially
expressed among samples (Figure 3 and see Additional
file 3). Classification of the normal tissues using the
uncentered data maintained some of the patterns
observed in Figure 2, for example, the gastrointestinal
organs, different parts of the heart, lymphoid tissues, lung
and trachea, and female reproductive organs. However,
placenta and PBMC were separate from the rest of tissues
in the hierarchical clustering because their miRNA expres-
sion levels were distinctive from those of other tissues
(Figure 3).
Estimated average copy numbers converted from CT val-
ues for all miRNAs examined in placenta and PBMC were
approximately 1,500 and 100 copies, respectively (Figure
4, and see Additional file 4 for complete copy number
data). Estimated average miRNA copy numbers from
these two tissue types were significantly different from
those of the rest of tissues (p = 0.0013 for placenta and p
= 4 × 10-71 for PBMC by Student's t test).
Three criteria were used to define universally expressed
miRNAs if their (1) average CT values in all tissues were
less than 30, (2) standard deviations of CT values in all tis-
sues were less than 0.8, and (3) their maximal and mini-
mal CT values in tissues differed by less than 4 (yellow
highlighted miRNAs in the Additional file 1). Since the 15
miRNAs identified, which include the 4 miRNAs used to
normalize our data (see Methods), showed rather consist-
ent expression levels in the extensive list of tissues we sur-
veyed, they would be strong candidates for normalizing
miRNA expression should the types of normal human tis-
sues beyond our list be examined. One of the 15 miRNAs,
miR-16, has been found abundantly expressed in all tis-
sues and was used as a control in several systems includ-
ing animal models [19].
Because we did not have replicate samples for most tissue
types, it is not sensible to use class prediction/marker dis-
covery programs to identify tissue-specific miRNA mark-
ers or differentially expressed miRNAs. Instead, we used
the following four criteria to select eight miRNA groups
(Figure 5). First, correlation coefficient (r) of the miRNA
expression patterns in the group was larger than 0.9. Sec-
ond, the miRNAs were differentially expressed in tissues
from similar anatomical locations and/or with similar
physiological functions as the clustering shown by Figures
3 and 5. Third, the miRNAs were preferentially expressed
in one tissue type or few organ sites that do not appear to
have obvious physiological link. Lastly, the miRNAs in
each group that are located at the same genomic cluster
were statistically overrepresented (by Chi-square test, see
below).
Group I (r = 0.937) that contains miR-1 and miR-133a/b
showed highest expression in different parts of the heart
and skeletal muscle as well as in vena cava, and in, unex-
pectedly, thyroid. This expression pattern is consistent
with previous observations in their localization and func-
tional analysis [8,20]. However, it was not previouslyBMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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appreciated that much lower expression of miR-1 and
miR-133a/b was seen in some non-heart, non-skeletal
muscle tissues. These are "hollow" organs composed of
smooth muscle-containing wall, such as the gastrointesti-
nal system, suggesting that expression of miR-1 and miR-
133a/b might mark some features shared by different
muscle types (i.e., skeletal, cardiac, and smooth). The
group II shown in Figure 5 included two subgroups with
similar expression patterns, in that miRNAs in the first
subgroup (miR-192 and miR-194, r = 0.988) had rather
focused expression in the gastrointestinal organs as well as
in kidney. The second subgroup was included despite
slightly lower correlation coefficient (r = 0.832) because it
appeared to be expressed mainly in organs lined with epi-
thelium, such as the gastrointestinal system, urinary sys-
tem, and lung, but not heart, muscle, lymphoid tissues,
liver, brain, and PBMC. Group III (r = 0.995) and group
IVa (r  = 0.96) miRNAs had preferential expression in
brain and PBMC, whereas concurrent lack of expression of
the group IVb miRNAs (r = 0.96) was seen in brain and
PBMC. Very low but specific expression of the members of
the mir-302 family and miR-367 and miR-499 (group V, r
= 0.995) was detected in different parts of the heart.
Expression of liver-specific miR-122a [21] was confirmed
by our data, but we also saw very low copy number of this
miRNA in brain (34 copies) and thymus (19 copies).
There were three subgroups (group VIIa, r = 0.998; group
VIIb, r = 0.992; group VIIc, r = 0.99) and two subgroups
(group VIIIa, r = 0.983; group VIIIb, r = 0.909) of miRNAs
that had preferential expression in placenta and testes,
respectively, as they had minimal expression in most
other tissues in each subgroup (Figure 5).
The miRNAs in some of the eight differentially expressed
groups identified in Figures 5 seemed to be localized
within the same genomic region, usually 1 to 5 kb apart
from each other (see Table 1 for chromosomal locations).
Two examples are the groups of miRNAs that had prefer-
ential expression in placenta and testes that are localized
in two separate genomic clusters at chromosomes
19q13.42 and Xq27.3, respectively. We used Chi-square
test to evaluate the statistical significance of the presence
of genomically clustered miRNAs in each expression
group based on the expected and observed frequency of
clustered miRNAs. This testing was rather stringent
because the clustering analysis on which the eight differ-
entially expressed groups were based primarily measured
the abundance of miRNAs; therefore, miRNAs that were
expressed at different levels in tissues would not be clus-
tered into the same expression group despite their similar
expression patterns among the tissues examined. The best
example is the three miRNAs (miR-381/154/377) in the
group VIIa that are located within a cluster of at least 32
miRNAs at chromosome 14q32.31. The other miRNAs in
the same genomic cluster were not in the group VIIa
because of their variable abundance. When centered data
were used, in which the expression pattern was primarily
measured, all these miRNAs were clustered together (rep-
resented by blue bar in Figure 2). For this reason, genom-
ically clustered miRNAs from all subgroups of the
differentially expressed groups VII or VIII, were evaluated
together. As summarized in Table 1, almost all miRNAs
located in the same genomic clusters were overrepre-
sented in the differentially expressed groups (in boxes,
with significant p values).
Intronic miRNAs and their host genes have correlated 
expression patterns in normal tissues
It is believed that miRNAs positioned in introns fre-
quently have the same expression patterns to their host
genes, and data from meta-analysis and RT-PCR have
been used to validate some of the genes [7,8]. We rea-
soned that our miRNA expression profiling could repro-
duce these observations.
We compiled a list of intronic miRNAs from a published
literature based on the following rules modified from a
previous report [7]: (1) the host gene and the miRNAs are
transcribed from the same strand of DNA; (2) the host
gene is a protein-coding gene with defined gene name and
Unsupervised hierarchical clustering of normal human tissues  based on the variation of miRNA abundance demonstrates  similar patterns as shown in Figure 2 Figure 3
Unsupervised hierarchical clustering of normal human tissues 
based on the variation of miRNA abundance demonstrates 
similar patterns as shown in Figure 2. Normalized CT for 
each assay was transformed into ∆CT against the average CT 
of all assays examined and clustered without centering the 
data. A pseudocolor scale outlines the CT values represented 
in the heat map. A detailed view of the clustering patterns of 
normal tissues is on the right.BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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The abundance of miRNAs in all tissues represented by the estimated average copy numbers of all miRNAs examined, as well  as by the average copy numbers of miRNAs in each of the eight most differentially expressed groups Figure 4
The abundance of miRNAs in all tissues represented by the estimated average copy numbers of all miRNAs examined, as well 
as by the average copy numbers of miRNAs in each of the eight most differentially expressed groups. Y-axis is the estimated 
copy number per cell (assuming 30 pg of total RNA in each cell), and the order of normal tissues at the X-axis is arranged by 
the clustering patterns shown in the Figure 3.BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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protein domains that link to its possible biological func-
tions; (3) the miRNA does not have extra copies in other
part of the genome since the transcription of each copy of
the miRNA gene could be regulated by different mecha-
nisms that would confound the result of our analyses.
Among the 31 miRNAs qualified (Table 2), 22 of them
had significant correlation (p < 0.05) with their host genes
in expression among 19 tissue types. If the two miRNAs
that had marginal correlation (p values between 0.05 and
0.07) was included (they could still be significant due to
the use of different databases in this comparative study),
total 77% of the miRNAs in our list had coherent expres-
sion patterns with their host genes. This result further cor-
roborates the hypothesis that expression of intronic
miRNAs is co-regulated with their host genes, and it also
identifies the host genes that could be surrogate markers
for expression of their intronic miRNAs.
Combination of predicting transcription factor binding 
sites, sequence comparison, and expression analyses 
identifies candidate factors contributing to the tissue-
specific expression of miRNA
We have shown that most of the miRNAs in the same dif-
ferentially expressed group are located within the same
genomic clusters, suggesting the presence of common reg-
ulatory mechanisms to their expression. Genomic
sequences flanking these clusters may contain regulatory
elements that control expression of these miRNAs. Pre-
dicting candidate transcription factors that might be asso-
ciated with tissue-specific expression of miRNAs would
offer valuable information to elucidate how miRNAs par-
ticipate in cell differentiation and tissue specification.
Although it is difficult to distinguish whether the presence
of a cis-regulatory element is truly functional or a stochas-
tic event without performing experimental validation
such as chromatin immunoprecipitation [20], it has been
shown that evolutionarily conserved non-coding genomic
sequences is more likely to have a functional role and a
better source to search transcription factor-binding sites
[22]. We sought to provide the proof of concept that a
comparative genomics-based resource using human and
mouse sequences such as GenomeTraFac [23] can detect
putative cis-regulatory regions that may contribute to tis-
sue-specific expression of miRNAs in some of the eight
differentially expressed groups (Figure 6A).
We first tested the feasibility by examining the 2 kb-
upstream sequence of the miR-1 cluster at chromosome
18 in the muscle-specific expression group because a
number of myogenic factors are known to bind to the
upstream sequences of muscle-specific miRNAs [20]. We
found one peak larger than 30 "Hits" (defined by the
number of transcription factor binding sites shared by
human and mouse within a 200 bp window), the maxi-
mal "Hits" value from the software's graphic output, with-
out particular surge of frequency of transcription factor-
binding site in both human and mouse sequences (see the
left "Hits" peak circled with red in the upper part of the
Additional file 5). The transcription factor-binding site
prediction showed two MyoD-binding sites in this region.
Another region close to the edge of this 2 kb segment had
another larger-than-30 "Hits" peak but no MyoD-binding
site was seen. There were another two peaks with "Hits"
close to 30 about 500 bp downstream to the MyoD-bind-
ing site-containing peak that actually had two MyoD-
binding sites (one for each, data not shown). We reasoned
that prioritizing the genomic sequences for subsequent
analysis would be critical if the transcription factor of our
interest is unknown (unlike MyoD in this test case), so we
chose the sequence with "Hits" larger than 30 as the first
criteria for transcription factor-binding site prediction.
The sequences from the graphic output generally showed
larger than 40% identical between human and mouse, so
we set 50% identical between human and mouse as a
threshold. Expression of the transcription factors binding
to the predicted sites was further examined in a host of
more than 60 normal human tissues from the database of
the Genomics Institute of the Novartis Research Founda-
tion (GNF) [24], and the transcription factors with the
same tissue distribution as the tissue-specific miRNAs
would conceivably be a favorable (certainly not only) tar-
get for future validation. We applied this searching strat-
egy to the three miRNAs in the group III (brain) and
identified a zinc finger protein, MOK-2 (ZFP239) (Figure
6B to 6D). Our heat map in Figure 5 also showed low but
detectable miR-129 in PBMC, testes, and pancreas, and
interestingly in this segment of sequence we identified
binding sites for STAT5, SOX5, and INSM1 that are specif-
ically expressed in these three tissues, respectively (see
Additional file 6).
This searching strategy would likely fail if the transcrip-
tion factor-binding sites are not conserved between
human and mouse although sequence homology in gen-
eral is acceptable (for example, 50% identical). This was
best represented by the search of transcription factors for
the group V and group VIII miRNAs. In the case of group
V, the upstream sequence of the miR-302b locus had a
peak of "Hits" but no binding site for heart-specific factors
could be found from that region. However, a region closer
to miR-302b showed a significant spike in binding-site
frequency despite the very low "Hits" (Figure 6E). Note
that the "Hits" and the transcription factor-binding site
frequency for mouse sequence in this region were
extremely low. Examining this DNA segment indeed
showed four binding sites for the heart-specific transcrip-
tion factor Nkx2-5 (see Additional file 7). GenomeTrafac
lacks data for most of the miRNAs in groups VII and VIII,
so we examined the miR-34b cluster that had prominent
expression in testes as well as in lung. In the regionBMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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An enlarge view of the eight groups of most differentially expressed miRNAs Figure 5
An enlarge view of the eight groups of most differentially expressed miRNAs. The pseudocolor scale is the same as that in Fig-
ure 3.BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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Table 1: Genomic locations of miRNAs in the 8 differentially expressed groups.
Ch Start End Strand p value*
Group I
hsa-mir-133b 6 52121680 52121798 +
hsa-mir-133a-1 18 17659657 17659744 -
hsa-mir-1-2 18 17662963 17663047 - 1.77 × 10-13
hsa-mir-1-1 20 60561958 60562028 +
hsa-mir-133a-2 20 60572564 60572665 +
Group II
hsa-mir-200b 1 1092347 1092441 +
hsa-mir-200a 1 1093106 1093195 +
hsa-mir-194-1 1 218358122 218358206 -
hsa-mir-375 2 219574611 219574674 -
hsa-mir-31 9 21502114 21502184 -
hsa-mir-192 11 64415185 64415294 - 0.000039
hsa-mir-194-2 11 64415403 64415487 -
hsa-mir-200c 12 6943123 6943190 +
hsa-mir-141 12 6943521 6943615 +
hsa-mir-203 14 103653495 103653604 +
Group III
hsa-mir-219-1 6 33283590 33283699 +
hsa-mir-129-1 7 127635161 127635232 +
hsa-mir-219-2 9 130194718 130194814 -
hsa-mir-129-2 11 43559520 43559609 +
hsa-mir-330 19 50834092 50834185 -
Group IVa
hsa-mir-124a-1 8 9798308 9798392 -
hsa-mir-124a-2 8 65454260 65454368 +
hsa-mir-124a-3 20 61280297 61280383 +
Group IVb
hsa-mir-214 1 170374561 170374670 - 0.000016
hsa-mir-199a-2 1 170380298 170380407 -
hsa-mir-143 5 148788674 148788779 +
hsa-mir-199b 9 130046821 130046930 -
hsa-mir-10a 17 44012199 44012308 -
hsa-mir-199a-1 19 10789102 10789172 -
Group V
hsa-mir-367 4 113788479 113788546 -
hsa-mir-302d 4 113788609 113788676 -
hsa-mir-302a 4 113788788 113788856 - 7.3 × 10-12
hsa-mir-302c 4 113788968 113789035 -
hsa-mir-302b 4 113789090 113789162 -
hsa-mir-499 20 33041840 33041961 +
Group VI
hsa-mir-122a 18 54269286 54269370 +
Group VIIa
hsa-mir-381 14 100582010 100582084 +
hsa-mir-154 14 100595845 100595928 +
hsa-mir-377 14 100598140 100598208 +
hsa-mir-498 19 58869263 58869386 +
hsa-mir-526b 19 58889459 58889541 +
hsa-mir-519b 19 58890279 58890359 +
hsa-mir-526a-1 19 58901318 58901402 +
hsa-mir-524 19 58906068 58906154 +BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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hsa-mir-517a 19 58907334 58907420 +
hsa-mir-517b 19 58916142 58916208 +
hsa-mir-516-3 19 58920508 58920592 + 0.026
hsa-mir-526a-2 19 58921988 58922052 +
hsa-mir-516-4 19 58931911 58932000 +
hsa-mir-517c 19 58936379 58936473 +
hsa-mir-527 19 58949084 58949168 +
hsa-mir-516-1 19 58951807 58951896 +
hsa-mir-516-2 19 58956199 58956288 +
hsa-mir-371 19 58982741 58982807 +
hsa-mir-503 X 133508024 133508094 -
Group VIIb
hsa-mir-184 15 77289185 77289268 +
hsa-mir-520e 19 58870777 58870863 +
hsa-mir-519e 19 58875006 58875089 +
hsa-mir-520f 19 58877225 58877311 +
hsa-mir-520a 19 58885947 58886031 +
hsa-mir-526b 19 58889459 58889541 +
hsa-mir-523 19 58893451 58893537 +
hsa-mir-520b 19 58896293 58896353 +
hsa-mir-526a-1 19 58901318 58901402 +
hsa-mir-520c 19 58902519 58902605 + 0.026
hsa-mir-518c 19 58903801 58903901 +
hsa-mir-524 19 58906068 58906154 +
hsa-mir-521-2 19 58911660 58911746 +
hsa-mir-526a-2 19 58921988 58922052 +
hsa-mir-518a-1 19 58926072 58926156 +
hsa-mir-518d 19 58929943 58930029 +
hsa-mir-518a-2 19 58934399 58934485 +
hsa-mir-521-1 19 58943702 58943788 +
hsa-mir-372 19 58982956 58983022 +
hsa-mir-373 19 58983771 58983839 +
hsa-mir-450-1 X 133502037 133502127 -
hsa-mir-450-2 X 133502204 133502303 -
Group VIIc
hsa-mir-512-1 19 58861745 58861828 +
hsa-mir-512-2 19 58864223 58864320 +
hsa-mir-515-1 19 58874069 58874151 +
hsa-mir-519e 19 58875006 58875089 +
hsa-mir-515-2 19 58880075 58880157 +
hsa-mir-519c 19 58881535 58881621 +
hsa-mir-520a 19 58885947 58886031 +
hsa-mir-525 19 58892599 58892683 +
hsa-mir-518f 19 58895081 58895167 +
hsa-mir-518b 19 58897803 58897885 +
hsa-mir-518c 19 58903801 58903901 +
hsa-mir-517a 19 58907334 58907420 +
hsa-mir-519d 19 58908413 58908500 + 0.026
hsa-mir-520d 19 58915162 58915248 +
hsa-mir-517b 19 58916142 58916208 +
hsa-mir-520g 19 58917232 58917321 +
hsa-mir-516-3 19 58920508 58920592 +
hsa-mir-518e 19 58924904 58924991 +
hsa-mir-518a-1 19 58926072 58926156 +
hsa-mir-516-4 19 58931911 58932000 +
hsa-mir-518a-2 19 58934399 58934485 +
hsa-mir-520h 19 58937578 58937665 +
hsa-mir-522 19 58946277 58946363 +
hsa-mir-516-1 19 58951807 58951896 +
hsa-mir-516-2 19 58956199 58956288 +
Table 1: Genomic locations of miRNAs in the 8 differentially expressed groups. (Continued)BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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Group VIIIa
hsa-mir-34b 11 110888873 110888956 +
hsa-mir-513-1 X 146102673 146102801 -
hsa-mir-513-2 X 146115036 146115162 - 0.00001
hsa-mir-507 X 146120194 146120287 -
hsa-mir-510 X 146161545 146161618 -
Group VIIIb
hsa-mir-449 5 54502117 54502207 -
hsa-mir-449b 5 54502231 54502327 -
hsa-mir-202 10 134911006 134911115 -
hsa-mir-34b 11 110888873 110888956 +
hsa-mir-34c 11 110889374 110889450 +
hsa-mir-506 X 146119930 146120053 -
hsa-mir-508 X 146126123 146126237 -
hsa-mir-509 X 146149742 146149835 - 0.00001
hsa-mir-514-1 X 146168457 146168554 -
hsa-mir-514-2 X 146171153 146171240 -
hsa-mir-514-3 X 146173851 146173938 -
*Whether each expression group was enriched in miRNAs located in genomic clusters was evaluated by Chi test. miRNAs in different subgroups 
were analyzed together in one test as long as they are located within a genomic cluster.
Table 1: Genomic locations of miRNAs in the 8 differentially expressed groups. (Continued)BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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upstream to the miR-34b locus, a segment with a spike of
transcription factor-binding site frequency in human
sequence (in this case a small spike in mouse sequence
too) and 25 "Hits" (Figure 6F) was examined and a fork-
head transcription factor, FOXF2, had a matching expres-
sion pattern with miR-34b in lung and placenta (see
Additional file 7). The binding site for SOX5 (a testis-
enriched factor, see Additional file 7) was present at the
binding-site peak region downstream to the miR-34b
locus, suggesting that both upstream and downstream
sequences to the transcript-start site should be examined.
Our results suggests that, using the GenomeTraFac web
tool, we can identify several candidate transcription fac-
tors that may participate in tissue-specific expression of
miRNAs by the following workflow (Figure 6A): (1) Start
from the 2 kb sequence upstream to the start of the
miRNA transcript, and start from the regions with peaks of
"Hits" larger than 30. (2) Examine the tissue distribution
of the transcription factors that bind to the regions in
comparison to the miRNA expression patterns. (3) If there
is no matched tissue distribution, repeat the search in the
2 kb sequence downstream to the start of the transcript.
(4) If the transcription factor-binding sites are not con-
served between human and mouse, look for regions with
low "Hits" but with increased transcription factor-binding
site frequency in human, followed by examining the tis-
sue distribution.
Predicted target genes of miRNAs with reduced expression 
in brain and peripheral blood mononuclear cells identifies 
a list of genes essential for development of these two tissue 
types in mouse models
Identification of genes whose expression is regulated by
miRNAs provides a lead for the functional roles of miR-
NAs, and predicting target genes of the tissue-specific miR-
NAs identified in our differentially expressed groups
would greatly facilitate understanding the miRNA-regu-
lated biological correlates of those tissues. One example is
the group IVb miRNAs that had almost no expression in
brain/PBMC compared to the rest of tissues that invaria-
bly had moderate to high abundance (Figure 5). Since cur-
rent evidence supports a general notion of opposite
expression levels between a miRNA and its target genes in
tissues [25], it is possible from this pattern of tissue distri-
bution that we may identify a list of genes targeted by
these miRNAs with suppressed expression in all tissues
but brain and PBMC.
One member of the miR-199a (miR-199a-2) is located at
only 5.6 kb away from miR-214, while miR-199a-1 and
miR-199b are located at two separate regions with no
other miRNAs nearby; miR-10a and miR-143 do not have
relationship with miR-199a/199b/214 in genomic struc-
ture and were excluded from the analysis. To validate the
low abundance of miR-199a/199b/214 in brain, their
expression was examined in 6 additional adult brain spec-
imens (including four derived from different regions of
the brain and one fetal brain specimens) and all were
reproducibly lower than the other tissue types (Table 3).
Lower expression of miR-199a/214 was previously
reported in brain than in liver, thymus, testes, and pla-
centa by 16 to 180 folds in a study using microarrays [16].
Interestingly, expression of miR-199a/214 in brain com-
pared to other major tissues was also reduced during
zebrafish embryonic development [26].
All target genes (N = 1939) for miR-199a/199b/214 pre-
dicted by the miRanda web tool from miRBase [27] were
combined, and their expression in 19 tissue types
extracted from the GNF database (see Methods) was
examined. To focus on more differentially expressed
genes, 1125 genes with variation in expression among tis-
sues equal or larger than 3.24 fold (1.8 under log2 base)
were selected for analysis. Unexpectedly, almost all genes
with reduced expression in non-brain and non-PBMC tis-
sues did not show simultaneous increased expression in
brain and PBMC; they rather showed elevated expression
in either one or the other (Figure 7). To reduce the chance
of selecting genes with stochastic increased expression in
brain or PBMC, we selected genes that only agglomerated
in unique expression clusters. There were 168 genes with
appreciable overexpression in brain, and 146 genes were
overexpressed in PBMC, whereas there were only 2 genes
had high expression in both tissues. Based upon these
expression patterns, these 314 genes (28% of genes ini-
tially selected for analysis) formed a more refined list of
candidates than the originally predicted target genes by
miRanda. Many of these 314 genes are required by the
nervous and hematopoietic systems in development as
well as in adult. The opposite expression pattern between
miR-199a/199b/214 and their 168 refined predicted tar-
gets in fetal/adult brain and non-brain tissues strongly
suggested that repressed expression of these three miRNAs
is important in brain development. One way to ultimately
test his hypothesis is to introduce loss-of-function muta-
tions of these genes in a mouse embryo.
International Gene Trap Consortium (IGTC) maintains a
database to curate functions of genes across the mouse
genome by gene trapping that is a high-throughput
approach to introduce insertional mutations and generate
loss-of-function alleles in embryonic stem cells [28].
There were 31 out of the 168 predicted brain targets that
had available phenotypic information in this database,
and 23 of the 31 genes had either defect in the nervous
system or in behavioral/neurological functions (Table 4
and see Additional file 8). To assure that such genes are
not overrepresented in the IGTC database, 33 genes that
had phenotypic information available were randomlyBMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
Page 13 of 20
(page number not for citation purposes)
Table 2: Correlation of expression patterns in human normal tissues between intronic miRNAs and their host genes.
miRNA Host Gene p value* Gene Description
miR-106b MCM7 0.047** MCM7 minichromosome maintenance deficient 7 (S. cerevisiae)
miR-107 PANK1 0.022 pantothenate kinase 1
miR-126 EGFL7 0.027 EGF-like-domain, multiple 7
miR-128a R3HDM1 0.002 R3H domain (binds single-stranded nucleic acids) containing 1
miR-128b ARPP-21 0.001 cyclic AMP-regulated phosphoprotein, 21 kD
miR-139 PDE2A 0.007 phosphodiesterase 2A, cGMP-stimulated
miR-140 AIP2 0.249 WW domain containing E3 ubiquitin protein ligase 2
miR-148b COPZ1 0.472 coatomer protein complex, subunit zeta 1
miR-149 GPC1 0.053 glypican 1
miR-151 PTK2 0.031 protein tyrosine kinase 2; focal adhesion kinase 1
miR-15b SMC4L1 0.003 SMC4 structural maintenance of chromosomes 4-like 1 (yeast)
miR-186 ZNF265 0.335 zinc finger protein 265
miR-188 CLCN5 0.07 chloride channel 5 (nephrolithiasis 2, X-linked, Dent disease)
miR-190 TLN2 0.001 talin 2
miR-196b HOXA9 0.005 homeo box A9
miR-204 TRPM3 0.009 transient receptor potential cation channel, subfamily M, member 3
miR-208 MYH6 6 × 10-30 myosin, heavy polypeptide 6, cardiac muscle, alpha
miR-211 TRPM1 0.004 transient receptor potential cation channel, subfamily M, member 1
miR-224 GABRE 0.006 gamma-aminobutyric acid (GABA) A receptor, epsilon
miR-25 MCM7 0.022 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae)
miR-28 LPP 0.023 LIM domain containing preferred translocation partner in lipoma
miR-30e NFYC 0.618 nuclear transcription factor Y, gamma
miR-326 ARRB1 0.013 arrestin, beta 1
miR-33 SREBF2 0.287 sterol regulatory element binding transcription factor 2
miR-335 MEST 0.006 mesoderm specific transcript homolog (mouse)
miR-338 AATK 0.0003 apoptosis-associated tyrosine kinase
miR-340 RNF130 0.346 ring finger protein 130
miR-342 EVL 0.017 Enah/Vasp-like
miR-346 GRID1 0.895 glutamate receptor, ionotropic, delta 1
miR-452 GABRE 0.0001 gamma-aminobutyric acid (GABA) A receptor, epsilon
miR-93 MCM7 0.022 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae)
*When multiple clones are available in the database, the clone with the best p value was chosen. **Pearson correlation; bold-type numbers indicate 
those with p values > 0.07
selected from 6991 genes recorded in the database as of
Feburary 13th, 2007, and only 7 genes had neurological
defects when mutated, indicating that functions in the
nervous system is indeed the most enriched category
among these 31 genes (p = 2 × 10-12 by Chi test). The same
strategy was used to evaluate the functional categories of
the 146 predicted PBMC targets that had 30 genes with
available phenotypic records in the database. Instead of 9
of the 33 randomly selected genes with defects in the
immune and/or hematopoietic systems, 14 of the pre-
dicted PBMC genes had phenotypic changes in these two
systems, which confirmed a moderate but still significant
enrichment of genes in this functional category (p =
0.002).
Our refined 314 predicted targets could be more enriched
than we observed in the functional categories of nervous
and immune systems because the IGTC database lacks
phenotypic records for most of these genes, and roles of
many of them (for example, interleukins, tumor necrosis
factors, ion channels, and neurotransmitter transporters)
in these two systems have been well documented.
Discussion
Our miRNA expression profiles provide comprehensive 
information about general abundance as well as tissue-
specificity of miRNAs
In this study, we examined the expression of miRNAs in a
comprehensive list of normal human tissues using 345
unique miRNA assays, and identified miRNAs that were
expressed in specific tissues with minimal or no expres-
sion in other tissues we examined, such as miR-129/219/
330 in brain, miR-124a/124b in brain and PBMC, and
two groups of miRNAs primarily expressed in placenta
and testes. We were also able to identify miRNAs with
moderate to high expression in all tissues examined
except for certain organs that had much lower or no
expression at all, such as miR-199a/199b/214 in brain
and PBMC and miR-10a/10b in brain.BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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A flow chart outlines the search strategy used to identify candidate transcription factors that might be associated with the tis- sue-specific expression of miRNAs in the most differentially expressed groups (A) Figure 6
A flow chart outlines the search strategy used to identify candidate transcription factors that might be associated with the tis-
sue-specific expression of miRNAs in the most differentially expressed groups (A). (B) A screen shot of the "regulogram" map 
from GenomeTraFac showed a peak for the "Hits" (red circle) upstream to the hsa-miR-129-2 (miR-129b) locus. (C) A screen 
shot of the transcription factor binding mapfrom GenomeTraFac showed four transcription factors with matching tissue distri-
bution with that of hsa-miR-129b. STAT, STAT5; INSM, INSM1; SORY, SOX5; MOKF, MOK-2 (ZFP239). (D) A screen shot 
from the GNF database showed the expression of MOK-2 (ZFP239) in normal mouse tissues (no data availablefor human tis-
sues). Two screen shots of the "regulogram" map from GenomeTraFac showed two regions of genomic sequences (red cir-
cles) close tothe hsa-miR-302b (E) and hsa-miR-34b (F) loci from which the binding sites for Nkx2-5 and FOXF2, respectively, 
were identified.BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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Our study provided an opportunity to re-visit and confirm
the tissue-specific miRNAs previously reported in litera-
ture. For example, liver-specific miR-122a had significant
expression in liver [13] and regulated cholesterol in
plasma [19]; we indeed saw no expression in all non-liver
tissues except for brain (34 copies) and thymus (19 cop-
ies) that had much less expression than liver (185-fold
and 332-fold less, respectively). One of the brain-specific
miRNAs, miR-219, described in a previous report [13] was
also confirmed with our data, in which brain had 85 cop-
ies and merely 5 copies were found in PBMC, and no
expression detected in the rest of the tissues.
For reasons such as limited types of tissues and number of
miRNAs examined and sensitivity of the assays, several
miRNAs that were previously considered as "tissue-spe-
cific" actually showed significant expression in other tis-
sues from our data, and therefore their tissue distribution
needs to be redefined. For example, one "brain-specific"
miRNA, miR-124 [29], was described in a number of
reports and was demonstrated to shift the expression pro-
files of HeLa cells towards the brain signature [30,31].
Although our data did show most abundant expression of
this miRNA in brain and no expression in most of the tis-
sues surveyed, it also had significant expression in PBMC
(from 1/4 to half of what was detected in brain) and
detectable in thymus and one of the testes (from 50- to
100-fold less than what was in brain). It would be more
reasonable to define miR-124a/b as preferentially
expressed in brain and PBMC.
In some cases, a broader tissue distribution for miRNAs
described from our data suggested that they might have
more functions than what was originally described. For
example, miR-375 that was identified as "pancreas islet-
specific" miRNA and functions as a regulator of insulin
secretion from the islet cells [32], but we clearly showed
that this miRNA belong to the epithelial subgroup of the
GI/epithelial expression cluster, and was preferentially
expressed in organs lined with epithelium (Group III in
Figure 3). It was proposed by the authors that miR-375
could be a pharmacological target for treating diabetes
[32], but the possibility of its functions in non-insulin-
secreting epithelial cells suggested by our data should not
be dismissed, especially any possible collateral effects
from other tissues when targeting miR-375 for pancreas
treatment is considered.
Not having enough tissue types for expression profiling
might cause incorrect denotation of tissue-specific expres-
sion. For example, miR-134 was found to regulate devel-
opment of dendritic spines of neurons, and regarded as
"brain-specific" [33], whereas our data clearly demon-
strated its expression in many other tissues with similar
(placenta and testis) or even higher (adrenal gland)
expression levels. We also discovered that another two
"brain-specific" miRNAs, miR-135 and miR-183, identi-
fied previously [13] were more abundant in several non-
brain tissues that were not examined in their original
report.
Universally expressed miRNAs are candidates 
participating fundamental metabolic pathways in normal 
cells
We identified a group of 15 miRNAs (see Additional file
1) that are universally expressed at similar levels in nor-
mal tissues we examined based upon their CT values and
the variability of their CT values among samples, and the
scope of our tissue collection suggests that these miRNAs
might exhibit similar expression patterns in tissues we did
not examined. Such a feature characterizes these miRNAs
as a candidate of universal reference to normalize miRNA
expression in normal human tissues, as we did in our
analysis using 4 miRNAs from this list.
The expression pattern and tissue distribution of these 15
miRNAs suggests that they might be associated with fun-
damental functions, such as metabolism, required for
normal human cells. For example, miR-29b was found to
control the amount of the branched-chain α-ketoacid
dehydrogenase complex that catalyzes the first irreversible
step in branched-chain amino acid catabolism [34]. Fur-
thermore, deregulated expression of these universally
expressed miRNAs could also link to pathological states of
a cell, such as neoplastic processes. Differential expression
of some of them in tumors has been demonstrated, for
example, miR-15/16 in chronic lymphocytic leukemia
[11], miR-92 in lymphoma and lung cancer [35], and
miR-140 in pancreatic cancer [36].
The clustering patterns of normal tissues by miRNA and 
mRNA expression profiles are similar
Even with much less degree of freedom than mRNAs,
miRNA expression profiles reflect the developmental lin-
eage and differentiation state of cells and successfully clas-
sified poorly differentiated tumors that could not have
definitive diagnosis by histopathology, while the classifi-
cation based upon the mRNA profiles was highly inaccu-
rate [14]. For this reason, one might anticipate that
miRNA expression profiles would classify normal human
tissues better than the mRNA profiles as well. To our sur-
prise, the clustering of tissues using the miRNA expression
profiles was very similar to that obtained by the mRNA
expression profiles. One possible explanation is that miR-
NAs preserve more of the "cellular identity signature"
compared to mRNAs under the genomic instability and
heterogeneity that characterize neoplastic cells, whereas in
normal tissues such a variable environment does not exist
so the performance of both miRNA and mRNA expression
profiles on tissue classification is comparable.BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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The uniqueness of the tissue clustering using the miRNA
expression profiles compared to that with the mRNA pro-
files appeared to be contributed by several groups of miR-
NAs with distinctive expression patterns, such as the ones
in epithelial tissues, and those in placenta, testes, brain,
and PBMC. The distinctive expression patterns in turn
highlight the central roles played by miRNAs in histogen-
esis of epithelial tissues and in key physiologies of pla-
centa, testis, brain, and the hematopoietic system. The
group of epithelial miRNAs is probably the best example
to support the concept of "cellular identity signature"
since they also have marked expression in cancer cell lines
derived from epithelial tissues [37].
Because a considerable portion of miRNAs had tissue-spe-
cific expression patterns and the average miRNA copy
numbers in all tissues were highly variable, global nor-
malization that assumes total abundance of the tran-
scripts from all genes is constant across different tissues
and is frequently used for normalization of mRNA expres-
sion data does not appear to be appropriate to normalize
miRNA expression data. This characteristic of miRNA
expression patterns among tissues we observed under-
scores the earlier findings in which total abundance of
miRNAs was altered in tumors [14] as well as in Dicer-
knockout animal models [38,39].
MicroRNA genes localized within a genomic cluster are 
preferentially co-expressed as a "transcription unit"
Chromosomal abnormalities such as deletion/amplifica-
tion of genes or loss/gain of chromosomes are character-
istics of neoplastic cells, and such features could influence
expression of genes within such afflicted regions that at
least some of these genes show a coherent expression pat-
tern, and this can be identified as distinctive expression
clusters when global profiles of mRNA expression are ana-
lyzed by hierarchical clustering. For example, epidermal
growth factor receptor (EGFR) is amplified in about 40%
of GBM, and gene expression profiling of GBM revealed
that EGFR and its neighboring genes were tightly clustered
together and had substantially increased expression in the
tumors that had EGFR amplification [40]. In the same
study, a cluster of six C-C motif-containing cytokines
located at Chromosome 17q12 within a 100 kb region
(with spacing from 3.5 kb to 35 kb between them) could
also be identified with a coordinated expression pattern,
suggesting the presence of a co-regulated mechanism of
transcription of these genes [40]. However, in most cases
mRNAs in a hierarchical cluster with highly correlated
expression are not mapped to the same genomic regions.
This provides a striking contrast to what was observed in
our miRNA expression profiles, in which most miRNAs
with similar expression patterns are encoded from the
same genomic region (usually with spacing from 1 kb to
5 kb between them). One possible explanation for this is
Table 3: The abundance of miR-199a/199b/214 in fetal/adult brain 
and non-brain/PBMC specimens (by average CT)
Tissues/CT/miRNAs hsa-miR-199a hsa-miR-199b hsa-miR-214
Ave non-brain/PBMC* 27.9 28.2 26.9
Fetal Brain 31.2 33.6 30.7
Brain 1 33.3 33.8 32.2
Brain 2 32.8 33.3 31.8
Brain 3 33.1 34.0 32.2
Frontal Cortex 33.6 35.0 32.2
Cerebellum 32.3 33.2 31.3
Occipital Cortex 34.2 35.0 32.9
Striatum 33.9 33.6 32.7
*p values between non-brain/PBMC tissues and all brain specimens by 
Student's t test: miR-199a, 4.1×10-8; miR-199b, 3.6×10-12; miR-214, 
1.5×10-10
The list of predicted target genes for miR-199a/199b/214 was  refined by their expression in 19 normal tissue types  extracted fromthe GNF database Figure 7
The list of predicted target genes for miR-199a/199b/214 was 
refined by their expression in 19 normal tissue types 
extracted fromthe GNF database. Blue bars on the right side 
of the heat map, genes with brain-specific expression; red 
bars, genes with PBMC-specific expression. The pseudocolor 
scale represents the gene expression level that has been 
transformed to the log2-based ratio to the average signal of 
all genes extracted.BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
Page 17 of 20
(page number not for citation purposes)
that most miRNA genes located within the same genomic
cluster are encoded in a polycistronic structure so they are
synthesized, processed, and mature to final products in a
parallel fashion. Conversely, miRNAs within the same
genomic region that share common expression pattern
would predict that these miRNA genes are transcribed as a
polycistron.
There were some exceptions in which miRNAs that are
localized in the same genomic cluster but did not show
coherent expression patterns in our data. This might be
caused by different regulatory mechanisms for the tran-
scription of these miRNAs, or these miRNAs share the
same transcript (polycistronic) but differential control of
the maturation process for each miRNA in the same tran-
script determines their final abundance.
Target genes predicted from miRNAs with low expression 
in brain and peripheral blood mononuclear cells are 
candidates required for development and maintenance of 
these two tissue types
It is believed that miRNAs down regulate the steady-state
levels of their target mRNAs, which has been demon-
strated in cell lines or entire organisms by examining lim-
ited number of miRNAs [19,30,41,42]. The major
drawback of these studies is that they investigated the
interaction between miRNAs and their target genes by
either overexpression or knockdown experiments, since
such an unnatural expression levels of miRNAs might
cause artifacts. The only study that investigates the associ-
ation of expression between miRNAs and their targets in
normal and neoplastic specimens derived from a spec-
trum of tissue types without modifying their expression
was using "tissue-specific" miRNAs extracted from other
sources and analyzed the expression of predicted target
genes of these miRNAs using published microarray data-
sets [25]. We used a comprehensive list of tissue speci-
mens and highly quantitative miRNA assays to identify
several groups of miRNAs that had specific expression in
certain tissues, and examined the expression of their pre-
dicted target genes in the same tissue types from public
microarray database.
We initially expected to observe complementary expres-
sion patterns of miRNAs and their predicted target genes
among the tissues, but in the case of miR-199a/199b/214
that had low expression in brain and PBMC compared to
the rest of tissues, most predicted targets that showed
brain/PBMC-specific expression only appeared in either
brain or PBMC but hardly both. Similarly, expression of
most predicted genes of miR-129/219/330 (higher expres-
sion in brain) had decreased expression in brain, but their
expression in non-brain tissues was highly variable. It
appears that expression of miRNA has a binary effect on
expression of its targets, in that the suppression of its tar-
get by the miRNA is predominant when miRNA expres-
sion is high, whereas when the miRNA expression is
reduced, other tissue-specific parameters such as tran-
scription factors serve as a different level of gene expres-
sion control. This is supported by the observation of the
same binary patterns in the expression of predicted
miRNA target genes in our data from other tumor speci-
mens and cell lines [37].
High-throughput identification of miRNA target genes
could potentially rely on either manipulating expression
of miRNAs (overexpression or knock-down) and examin-
ing resulting changes of gene expression profiles in cells/
tissues using microarrays, or algorithm prediction fol-
lowed by in vitro validation. Although in silico prediction
appears to circumvent the time and cost issues associated
with the transfection/knock-down experiments and
microarrays, a long list of predicted output could be frus-
trating for investigators to focus on a few candidates for
validation. Furthermore, genes predicted as targets might
not be biologically meaningful if the miRNAs and their
predicted target genes are never expressed in the same tis-
sues. In our study, we filtered the original list of predicted
targets by comparison of the tissue distribution between
miRNAs and their target genes. This strategy seemed to
produce a much-focused group of genes corresponding to
the physiological functions of the organs. For example,
many predicted target genes of miR-199a/199b/214 (low
expression in brain and PBMC) are required by the devel-
oping nervous and hematopoietic systems.
Conclusion
Our data and analyses of expression patterns presented a
global view of tissue distribution of miRNAs and the rela-
tion to their chromosomal locations. We presented evi-
dence that such data support identification of specific
miRNAs as markers to correlate with the functions of nor-
mal or disease tissues in which these miRNAs are
expressed, and identification of the predicted miRNA tar-
get genes that are required in the developing nervous and
hematopoietic systems. We also demonstrated a proof-of-
principle strategy using the GenomeTraFac web source to
precede future experimental validation for identifying
candidate transcription factors associated with tissue-spe-
cific expression of miRNAs.
Methods
Total RNA samples
Total RNA samples of normal human tissues from com-
mercial sources were purchased from Ambion (Austin,
TX), Stratagene (La Jolla, CA), and BD Biosciences (Moun-
tain View, CA).BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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Quantitation of miRNAs
TaqMan® MicroRNA Assays were used to quantitate miR-
NAs in all of our studies according to the conditions pub-
lished previously [17]. In brief, each 7.5 µl RT reaction
contained purified 3.75 ng of total RNA, 50 nM stem-loop
RT primer (Applied Biosystems, Foster City, CA), 1×RT
buffer (Applied Biosystems), 0.25 mM each of dNTPs,
3.33 U/µl MultiScribe™ reverse transcriptase (Applied Bio-
systems) and 0.25 U/µl RNase inhibitor (Applied Biosys-
tems). The reactions were incubated in an Applied
Biosystems 9700 Thermocycler in a 384-well plate for 30
min at 16°C, 30 min at 42°C, followed by 5 min at 85°C,
and then held at 4°C. RT products were diluted three
times with H2O prior to setting up PCR reaction. Each
real-time PCR for each microRNA assay (10 µl volume)
was carried out in quadruplicate, and each 10 µl reaction
mixture included 2 µl of diluted RT product, 5 µl of
2×TaqMan® Universal PCR Master Mix, 0.2 µM TaqMan®
probe, 1.5 µM forward primer, and 0.7 µM reverse primer,
respectively. The reaction was incubated in an Applied
Biosystems 7900HT Fast Real-Time PCR System in 384-
well plates at 95°C for 10 min, followed by 40 cycles of
95°C for 15 sec and 60°C for 1 min. The threshold cycle
(CT) is defined as the fractional cycle number at which the
fluorescence exceeds the fixed threshold of 0.2. Auto-
mated multi-well distribution of samples was done using
the HYDRA® II PLUS-ONE System (Matrix Technologies,
Hudson, NH).
Data adjustment and filtering for hierarchical clustering
Four human miRNAs (miR-30e, miR-92, miR-92N, and
miR-423) that were least variable among the 40 normal
tissues in this study were identified, and the average quan-
tity of these four in each tissue was used to normalize the
RNA input. Normalized data from assays with CT values
greater than 35 were treated as 35 and were subject to hier-
archical clustering by two ways. One is mean-centering
data for each miRNA but not tissues, followed by correla-
tion similarity metrics for both miRNA and tissue cluster-
ing (Figure 2); the other was to use Euclidean similarity
metric and correlation similarity metric to cluster miRNAs
and samples, respectively, without centering the data (Fig-
ure 3). We also normalized the sample input by quantitat-
ing small nuclear RNAs using the TaqMan® MicroRNA
Assay Controls (Applied Biosystems), and the key patterns
of the hierarchical clustering of both miRNAs and tissues
were very similar (data not shown, and see Additional file
1 for data normalized by small nuclear RNAs). The copy
number of miRNAs in each cell (assuming each cell con-
tains 30 pg of total RNA) was calculated from a formula
 that was estimated using synthetic lin-
4 miRNA [17].
When gene expression data were extracted from the GNF
[43] database, the signal intensity of each gene was
divided by the average of signal intensities of all genes
extracted, followed by log2 transformation. Data adjust-
ment for centering and similarity metric for hierarchical
clustering was the same as described above. Differentially
expressed genes were selected to avoid spurious clustering
results by removing genes with variation in expression
among tissues less than 1.8 (under log2 base). Higher cut-
off will generate less number of genes and therefore was
avoided. Genes from the Stanford GBM database were
selected if they had analyzable data in more than 80% of
the samples among the tissues examined.
Extraction of data from public databases
Genomic sequence of miRNA cluster and the predicted
transcription factor binding sites were extracted from the
"Cis-element clusters within BlastZ Aligments" option at
the GenomeTraFac [44]. Tissue distribution of selected
genes was derived from the GNF database [43], in which
the expression data from the same tissue types examined
in our study were extracted for analyses. Target genes of
miRNAs were predicted using the miRanda open-source
software [45] associated with the miRBase [46] with a cut-
off p value less than 0.05. The IGTC database [47] was
used to search the phenotype of mice carrying loss-of-
function mutations.
Statistical analyses
The correlation coefficient (r) between repeating speci-
mens and the correlation of expression between intronic
miRNAs and their host genes (threshold p value was set to
0.05) were analyzed using Pearson regression. Compari-
10 22 40 3 34 () / . / − CT
Table 4: Phenotypic changes in mice carrying loss-of-function 
mutations of the predicted brain and PBMC target genes.
Phenotype Brain PBMC Random
Nervous system1 21 5 5
Immune system2 28 7
Nervous/immune3 26 2
Embryonic lethal4 20 4
Other systems5 34 1 1
Normal6 17 4
Total gene number 31 30 33
1 Phenotype in nervous system, including behavioral and neurological 
defects, but no defects in immune and hematopoietic system.
2 Phenotype in immune system, including the hematopoietic system, 
but no nervous system or behavioral/neurological defects.
3 Phenotype from both 1 and 2 can be seen.
4 Embryonic lethal with no other phenotypic records, indicating that 
the embryo dies too early to observe meaningful phenotype.
5 Defects in other tissues/organs/systems than nervous and immune 
systems.
6 The phenotypic record showed no defect was seen.BMC Genomics 2007, 8:166 http://www.biomedcentral.com/1471-2164/8/166
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son of mean was evaluated using 1-tail Student's t test
with unequal variance. Chi test was used to analyze the
significance of genomically clustered miRNAs in each dif-
ferentially expressed group: the expected frequency was
the number of all miRNAs among the 345 miRNAs exam-
ined that are located within the genomic clusters carrying
the genomically clustered miRNAs regardless whether or
not they were in the differentially expressed groups.
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